(Q35936252)

11 August 2017

1 reference

title

Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics (English)

1 reference

11 August 2017

5

Siegfried Kasper

0 references

author name string

Nikolas Klein

1

1 reference

11 August 2017

Julia Sacher

2

1 reference

11 August 2017

Helene Wallner

3

1 reference

11 August 2017

Johannes Tauscher

4

1 reference

11 August 2017

publication date

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

9

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

823-832

1 reference

Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Lithium augmentation therapy in refractory depression-update 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Cognitive effects and antipsychotic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Major tranquillisers used as antidepressants. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

A Study of Refractory Cases of Depressive Illnesses and their Response to Combined Antidepressant Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Paroxetine augmentation with risperidone in therapy-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Treatment resistant depression: methodological overview and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Natural history and preventative treatment of recurrent mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Definition and epidemiology of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

[Effects of electroconvulsive therapy on cognitive functions in therapy-refractory depression]

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

ECT response in delusional versus non-delusional depressed inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Die Elektrokonvulsionstherapie in der klinischen Praxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

Citalopram and Bupropion-SR

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Mirtazapine augmentation in the treatment of refractory depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Three- to 5-year prospective follow-up of outcome in major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Lithium Carbonate Versus Cognitive Therapy as Sequential Combination Treatment Strategies in Partial Responders to Antidepressant Medication

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

How much do novel antipsychotics benefit the patients?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Study duration in antidepressant research: advantages of a 12-week trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Combined MAO-inhibitor and tri- (tetra) cyclic antidepressant treatment in therapy resistant depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Expérimentation Psychopharmacologique

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

SSRI combination treatment for depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Pindolol augmentation of treatment-resistant depressed patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Amisulpride versus amineptine and placebo for the treatment of dysthymia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Tranylcypromine plus risperidone for treatment-refractory major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002248

7 January 2021

10.1017/S1092852900002248

Identifiers

DOI

1 reference

11 August 2017

1 reference